PAP
RCKT icon

Persistent Asset Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Persistent Asset Partners’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,731
Closed -$27.7K – 887
2026
Q1 		$27.7K Buy
+7,731
New +$30.7K 0.01% 272

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Persistent Asset Partners's RCKT Position: Q2 2026 in Review

Persistent Asset Partners sold out of Rocket Pharmaceuticals (RCKT) in Q2 2026, closing a stake of 7,731 shares — an estimated $27.7K sold.

Persistent Asset Partners first reported a position in RCKT in Q1 2026 and held it in 1 quarter. The position peaked at $27.7K in Q1 2026. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Persistent Asset Partners reported no remaining Rocket Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 7,731 Rocket Pharmaceuticals shares in Q2 2026, an estimated $27.7K.
  • Persistent Asset Partners first reported a position in Rocket Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Persistent Asset Partners's Rocket Pharmaceuticals position peaked at $27.7K in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.